AIM
NBIX icon

Aigen Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Aigen Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,948
Closed -$685K – 911
2024
Q3 		$685K Buy
+5,948
New +$815K 0.13% 224
2024
Q2 		– Sell
-4,801
Closed -$662K – 936
2024
Q1 		$662K Buy
+4,801
New +$656K 0.14% 220
2022
Q4 		– Sell
-25,157
Closed -$2.67M – 692
2022
Q3 		$2.67M Buy
+25,157
New +$2.55M 0.38% 72
2022
Q1 		– Sell
-2,837
Closed -$233K – 892
2021
Q4 		$233K Buy
+2,837
New +$261K 0.01% 884
2021
Q3 		– Sell
-7,806
Closed -$760K – 596
2021
Q2 		$760K Buy
7,806
+2,378
+44% +$228K 0.13% 173
2021
Q1 		$528K Buy
+5,428
New +$569K 0.07% 283
2020
Q4 		– Sell
-6,937
Closed -$667K – 948
2020
Q3 		$667K Buy
6,937
+3,362
+94% +$389K 0.09% 345
2020
Q2 		$436K Sell
3,575
-4,349
-55% -$481K 0.06% 506
2020
Q1 		$686K Sell
7,924
-1,374
-15% -$134K 0.09% 325
2019
Q4 		$999K Buy
+9,298
New +$974K 0.17% 181

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aigen Investment Management's NBIX Position: Q4 2024 in Review

Aigen Investment Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 5,948 shares — an estimated $685K sold.

Aigen Investment Management first reported a position in NBIX in Q4 2019 and held it in 10 quarters. The position peaked at $2.67M in Q3 2022. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

  • Aigen Investment Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
  • Aigen Investment Management sold 5,948 Neurocrine Biosciences shares in Q4 2024, an estimated $685K.
  • Aigen Investment Management first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 10 quarters.
  • Aigen Investment Management's Neurocrine Biosciences position peaked at $2.67M in Q3 2022.
  • 600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Aigen Investment Management's 13F filing for Q4 2024, filed 6 Feb 2025.